Evidence map›Paper›PMID 42137591›Full record

ArticleMolecular therapy. Advances2026

Development of bicistronic plasmids and fusion proteins for clinical translation of tumor immune reprogramming.

Joanna Yang, Sabrina S Chen, Ethan Idnani, Sydney R Shannon, Kathryn Luly, Charina S Fabilane, D Scott Wilson, Jamie B Spangler, Stephany Y Tzeng, Jordan J Green

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joanna YangDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Sabrina S ChenDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Ethan IdnaniDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Sydney R ShannonDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Kathryn LulyDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Charina S FabilaneTranslational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
D Scott WilsonDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Jamie B SpanglerDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Stephany Y TzengDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Jordan J GreenDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
Training/Dissemination-Resource for Molecular Imaging Agents in Precision MedicineP41EB024495 · NIBIB · UT SOUTHWESTERN MEDICAL CENTER · PI MARTIN G POMPER · 2017 to 2026
$11.8M
TR&D Project 3P41EB028239 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI Jordan Green, JONATHAN P SCHNECK · 2019 to 2026
$11.5M
A PLATFORM TECHNOLOGY TO GENETICALLY REPROGRAM CANCER CELLS FOR ENHANCED IMMUNOTHERAPYR37CA246699 · NCI · JOHNS HOPKINS UNIVERSITY · PI TZENG, STEPHANY YI · 2020 to 2025
$2.6M
Gene Delivery Nanoparticles to Treat GlioblastomaR01CA228133 · NCI · JOHNS HOPKINS UNIVERSITY · PI GREEN, JORDAN · 2019 to 2023
$1.9M
Immunoengineered nanotechnology for targeted expansion of regulatory T cellsR01EB029455 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI SPANGLER, JAMIE BERTA · 2020 to 2023
$1.7M
NCI NIH HHS P30 CA006973NCI NIH HHS R01 CA228133NCI NIH HHS R37 CA246699NIBIB NIH HHS P41 EB024495NIBIB NIH HHS P41 EB028239NIBIB NIH HHS R01 EB029455
6 · The paper itself

Abstract

Delivery of 4-1BB ligand (4-1BBL) and interleukin 12 (IL-12) via poly(β-amino ester) (PBAE) nanoparticles (NPs) enables reprogramming of tumor cells into tumor-associated antigen-presenting cells (tAPCs), stimulating anti-tumor immune responses. Existing work on 4-1BBL/IL-12 NPs employs a dual-plasmid system and plasmid backbones containing antibiotic selection, both of which represent challenges for clinical translation. Production of two plasmids adds manufacturing complexity and costs, with amplification and purification processes required for both plasmids. Additionally, regulatory agencies discourage the use of antibiotic-resistance components in gene therapies due to concerns around rising antibiotic resistance. Here, we describe an approach to address manufacturing and regulatory challenges in translating 4-1BBL/IL-12 NPs into the clinic by engineering bicistronic plasmids co-expressing 4-1BBL and IL-12 via a T2A peptide or a (G

Indexed as

bioengineeringcancergene deliverygene therapyimmunoengineeringimmunotherapymelanomanon-viralplasmidT cell

Identifiers

PMID42137591
PMCPMC13148935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.